{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:50:47Z","timestamp":1790725847512,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40263-026-01275-y","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:30:25Z","timestamp":1771353025000},"page":"509-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pathological Protein Targets in Parkinson\u2019s Disease: Progress Towards the Development of Disease-Modifying Therapies"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9121-0294","authenticated-orcid":false,"given":"Nicolas","family":"Dzamko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"3","key":"1275_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JPD-230376","volume":"14","author":"SY Lim","year":"2024","unstructured":"Lim SY, Klein C. Parkinson\u2019s disease is predominantly a genetic disease. J Parkinsons Dis. 2024;14(3):467\u201382.","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"1275_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/WCO.0000000000001167","volume":"36","author":"A Cherian","year":"2023","unstructured":"Cherian A, Puthenveedu KD, Vijayaraghavan A. Parkinson\u2019s disease\u2014genetic cause. Curr Opin Neurol. 2023;36(4):292\u2013301.","journal-title":"Curr Opin Neurol"},{"key":"1275_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/genes13030471","author":"F Jia","year":"2022","unstructured":"Jia F, Fellner A, Kumar KR. Monogenic Parkinson\u2019s disease: genotype, phenotype, pathophysiology, and genetic testing. Genes. 2022. https:\/\/doi.org\/10.3390\/genes13030471.","journal-title":"Genes"},{"issue":"1","key":"1275_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00933-0","volume":"11","author":"LM Lange","year":"2025","unstructured":"Lange LM, Cerquera-Cleves C, Schipper M, Panagiotaropoulou G, Braun A, Kraft J, et al. Prioritizing Parkinson\u2019s disease risk genes in genome-wide association loci. NPJ Parkinsons Dis. 2025;11(1):77.","journal-title":"NPJ Parkinsons Dis"},{"issue":"6645","key":"1275_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature"},{"issue":"5321","key":"1275_CR6","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276(5321):2045\u20137.","journal-title":"Science"},{"issue":"7","key":"1275_CR7","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.bpj.2010.06.035","volume":"99","author":"T Bartels","year":"2010","unstructured":"Bartels T, Ahlstrom LS, Leftin A, Kamp F, Haass C, Brown MF, et al. The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys J. 2010;99(7):2116\u201324.","journal-title":"Biophys J"},{"key":"1275_CR8","doi-asserted-by":"crossref","unstructured":"Vekrellis K, Emmanouilidou E, Xilouri M, Stefanis L. alpha-Synuclein in Parkinson\u2019s disease: 12 years later. Cold Spring Harb Perspect Med. 2024;14(11):a041645.","DOI":"10.1101\/cshperspect.a041645"},{"issue":"9440","key":"1275_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","volume":"364","author":"MC Chartier-Harlin","year":"2004","unstructured":"Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. Lancet. 2004;364(9440):1167\u20139.","journal-title":"Lancet"},{"issue":"5646","key":"1275_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson\u2019s disease. Science. 2003;302(5646):841.","journal-title":"Science"},{"issue":"1","key":"1275_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ana.25274","volume":"84","author":"L Pihlstrom","year":"2018","unstructured":"Pihlstrom L, Blauwendraat C, Cappelletti C, Berge-Seidl V, Langmyhr M, Henriksen SP, et al. A comprehensive analysis of SNCA-related genetic risk in sporadic Parkinson disease. Ann Neurol. 2018;84(1):117\u201329.","journal-title":"Ann Neurol"},{"issue":"19","key":"1275_CR12","doi-asserted-by":"publisher","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","volume":"287","author":"B Fauvet","year":"2012","unstructured":"Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, et al. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287(19):15345\u201364.","journal-title":"J Biol Chem"},{"issue":"5","key":"1275_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"JY Li","year":"2008","unstructured":"Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501\u20133.","journal-title":"Nat Med"},{"key":"1275_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.reth.2023.12.019","volume":"25","author":"S Gima","year":"2024","unstructured":"Gima S, Oe K, Nishimura K, Ohgita T, Ito H, Kimura H, et al. Host-to-graft propagation of inoculated alpha-synuclein into transplanted human induced pluripotent stem cell-derived midbrain dopaminergic neurons. Regen Ther. 2024;25:229\u201337.","journal-title":"Regen Ther"},{"issue":"6109","key":"1275_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949\u201353.","journal-title":"Science"},{"issue":"2","key":"1275_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"1275_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1436262","volume":"18","author":"S Zampar","year":"2024","unstructured":"Zampar S, Di Gregorio SE, Grimmer G, Watts JC, Ingelsson M. \u201cPrion-like\u201d seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders. Front Neurosci. 2024;18:1436262.","journal-title":"Front Neurosci"},{"issue":"1","key":"1275_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs. 2024;38(1):5\u201322.","journal-title":"BioDrugs"},{"issue":"1","key":"1275_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12770-x","volume":"272","author":"M Alfaidi","year":"2024","unstructured":"Alfaidi M, Barker RA, Kuan WL. An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease. J Neurol. 2024;272(1):21.","journal-title":"J Neurol"},{"issue":"2","key":"1275_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mds.26878","volume":"32","author":"DB Schenk","year":"2017","unstructured":"Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, et al. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017;32(2):211\u20138.","journal-title":"Mov Disord"},{"key":"1275_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104582","volume":"132","author":"DJ Schofield","year":"2019","unstructured":"Schofield DJ, Irving L, Calo L, Bogstedt A, Rees G, Nuccitelli A, et al. Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019;132:104582.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1275_CR22","doi-asserted-by":"publisher","first-page":"1994690","DOI":"10.1080\/19420862.2021.1994690","volume":"13","author":"L Fjord-Larsen","year":"2021","unstructured":"Fjord-Larsen L, Thougaard A, Wegener KM, Christiansen J, Larsen F, Schroder-Hansen LM, et al. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs. 2021;13(1):1994690.","journal-title":"MAbs"},{"key":"1275_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","volume":"124","author":"A Weihofen","year":"2019","unstructured":"Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, et al. Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models. Neurobiol Dis. 2019;124:276\u201388.","journal-title":"Neurobiol Dis"},{"key":"1275_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105543","volume":"161","author":"E Nordstrom","year":"2021","unstructured":"Nordstrom E, Eriksson F, Sigvardson J, Johannesson M, Kasrayan A, Jones-Kostalla M, et al. ABBV-0805, a novel antibody selective for soluble aggregated alpha-synuclein, prolongs lifespan and prevents buildup of alpha-synuclein pathology in mouse models of Parkinson\u2019s disease. Neurobiol Dis. 2021;161:105543.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"1275_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N Engl J Med. 2022;387(5):421\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"1275_CR26","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. Trial of cinpanemab in early Parkinson\u2019s disease. N Engl J Med. 2022;387(5):408\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"1275_CR27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med. 2024;30(4):1096\u2013103.","journal-title":"Nat Med"},{"issue":"7794","key":"1275_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating alpha-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature. 2020;578(7794):273\u20137.","journal-title":"Nature"},{"issue":"10468","key":"1275_CR29","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/S0140-6736(24)01883-X","volume":"404","author":"MT Heneka","year":"2024","unstructured":"Heneka MT, Morgan D, Jessen F. Passive anti-amyloid beta immunotherapy in Alzheimer\u2019s disease-opportunities and challenges. Lancet. 2024;404(10468):2198\u2013208.","journal-title":"Lancet"},{"issue":"5","key":"1275_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinsons Dis. 2024;14(5):899\u2013912.","journal-title":"J Parkinsons Dis"},{"issue":"11","key":"1275_CR31","doi-asserted-by":"publisher","first-page":"948","DOI":"10.4161\/hv.6.11.13217","volume":"6","author":"A Schneeberger","year":"2010","unstructured":"Schneeberger A, Mandler M, Mattner F, Schmidt W. AFFITOME(R) technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin. 2010;6(11):948\u201352.","journal-title":"Hum Vaccin"},{"issue":"6","key":"1275_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","volume":"127","author":"M Mandler","year":"2014","unstructured":"Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson\u2019s disease clinical trials. Acta Neuropathol. 2014;127(6):861\u201379.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1275_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","volume":"19","author":"D Volc","year":"2020","unstructured":"Volc D, Poewe W, Kutzelnigg A, Luhrs P, Thun-Hohenstein C, Schneeberger A, et al. Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19(7):591\u2013600.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1275_CR34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3233\/JPD-212594","volume":"11","author":"W Poewe","year":"2021","unstructured":"Poewe W, Volc D, Seppi K, Medori R, Luhrs P, Kutzelnigg A, et al. Safety and tolerability of active immunotherapy targeting alpha-synuclein with PD03A in patients with early Parkinson\u2019s disease: a randomized, placebo-controlled, phase 1 study. J Parkinsons Dis. 2021;11(3):1079\u201389.","journal-title":"J Parkinsons Dis"},{"key":"1275_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol Neurodegener. 2016;11:7.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1275_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13195-020-00727-x","volume":"12","author":"JT Nimmo","year":"2020","unstructured":"Nimmo JT, Verma A, Dodart JC, Wang CY, Savistchenko J, Melki R, et al. Novel antibodies detect additional alpha-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alzheimers Res Ther. 2020;12(1):159.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1275_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00401-021-02381-5","volume":"143","author":"JT Nimmo","year":"2022","unstructured":"Nimmo JT, Smith H, Wang CY, Teeling JL, Nicoll JAR, Verma A, et al. Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric alpha-synuclein accumulation in the brain and gut. Acta Neuropathol. 2022;143(1):55\u201373.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1275_CR38","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/mds.29016","volume":"37","author":"HJ Yu","year":"2022","unstructured":"Yu HJ, Thijssen E, van Brummelen E, van der Plas JL, Radanovic I, Moerland M, et al. A randomized first-in-human study with UB-312, a UBITh(R) alpha-synuclein peptide vaccine. Mov Disord. 2022;37(7):1416\u201324.","journal-title":"Mov Disord"},{"issue":"9","key":"1275_CR39","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","volume":"30","author":"P Eijsvogel","year":"2024","unstructured":"Eijsvogel P, Misra P, Concha-Marambio L, Boyd JD, Ding S, Fedor L, et al. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological alpha-synuclein: a phase 1 placebo-controlled trial. Nat Med. 2024;30(9):2631\u201340.","journal-title":"Nat Med"},{"issue":"1","key":"1275_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00552-7","volume":"9","author":"DL Price","year":"2023","unstructured":"Price DL, Khan A, Angers R, Cardenas A, Prato MK, Bani M, et al. In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2023;9(1):114.","journal-title":"NPJ Parkinsons Dis"},{"issue":"10","key":"1275_CR41","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit JW, Basile P, Prato MK, Detalle L, Mathy FX, Schmidt A, et al. Phase 1\/1b studies of UCB0599, an oral inhibitor of alpha-synuclein misfolding, including a randomized study in Parkinson\u2019s disease. Mov Disord. 2022;37(10):2045\u201356.","journal-title":"Mov Disord"},{"issue":"6","key":"1275_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 2013;125(6):795\u2013813.","journal-title":"Acta Neuropathol"},{"key":"1275_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104021","volume":"80","author":"J Levin","year":"2022","unstructured":"Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, et al. Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine. 2022;80:104021.","journal-title":"EBioMedicine"},{"issue":"5","key":"1275_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-015-1483-3","volume":"130","author":"J Wagner","year":"2015","unstructured":"Wagner J, Krauss S, Shi S, Ryazanov S, Steffen J, Miklitz C, et al. Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol. 2015;130(5):619\u201331.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1275_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","volume":"5","author":"DI Finkelstein","year":"2017","unstructured":"Finkelstein DI, Billings JL, Adlard PA, Ayton S, Sedjahtera A, Masters CL, et al. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease. Acta Neuropathol Commun. 2017;5(1):53.","journal-title":"Acta Neuropathol Commun"},{"key":"1275_CR46","doi-asserted-by":"publisher","first-page":"1197853","DOI":"10.3389\/fnmol.2023.1197853","volume":"16","author":"V Brembati","year":"2023","unstructured":"Brembati V, Faustini G, Longhena F, Bellucci A. Alpha synuclein post translational modifications: potential targets for Parkinson\u2019s disease therapy? Front Mol Neurosci. 2023;16:1197853.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"1275_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","volume":"9","author":"JM Taymans","year":"2023","unstructured":"Taymans JM, Fell M, Greenamyre T, Hirst WD, Mamais A, Padmanabhan S, et al. Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis. 2023;9(1):104.","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"1275_CR48","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601\u20137.","journal-title":"Neuron"},{"issue":"4","key":"1275_CR49","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"C Paisan-Ruiz","year":"2004","unstructured":"Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron. 2004;44(4):595\u2013600.","journal-title":"Neuron"},{"issue":"1","key":"1275_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-025-00881-9","volume":"11","author":"C Kruger","year":"2025","unstructured":"Kruger C, Lim SY, Buhrmann A, Fahrig FL, Gabbert C, Bahr N, et al. Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2025;11(1):30.","journal-title":"NPJ Parkinsons Dis"},{"issue":"46","key":"1275_CR51","doi-asserted-by":"publisher","first-page":"16842","DOI":"10.1073\/pnas.0507360102","volume":"102","author":"AB West","year":"2005","unstructured":"West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA. 2005;102(46):16842\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1275_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1042\/BJ20091035","volume":"424","author":"RJ Nichols","year":"2009","unstructured":"Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson\u2019s disease. Biochem J. 2009;424(1):47\u201360.","journal-title":"Biochem J"},{"issue":"164","key":"1275_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004485","volume":"4","author":"Z Sheng","year":"2012","unstructured":"Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med. 2012;4(164):164ra1.","journal-title":"Sci Transl Med"},{"key":"1275_CR54","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12813","author":"M Steger","year":"2016","unstructured":"Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016. https:\/\/doi.org\/10.7554\/eLife.12813.","journal-title":"Elife"},{"issue":"17","key":"1275_CR55","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1042\/BCJ20220161","volume":"479","author":"AF Kalogeropulou","year":"2022","unstructured":"Kalogeropulou AF, Purlyte E, Tonelli F, Lange SM, Wightman M, Prescott AR, et al. Impact of 100 LRRK2 variants linked to Parkinson\u2019s disease on kinase activity and microtubule binding. Biochem J. 2022;479(17):1759\u201383.","journal-title":"Biochem J"},{"issue":"2","key":"1275_CR56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BST20180462","volume":"47","author":"JH Kluss","year":"2019","unstructured":"Kluss JH, Mamais A, Cookson MR. LRRK2 links genetic and sporadic Parkinson\u2019s disease. Biochem Soc Trans. 2019;47(2):651\u201361.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"1275_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00738-4","volume":"19","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Li H, Sreeram K, Malankhanova T, Boddu R, Strader S, et al. Single molecule array measures of LRRK2 kinase activity in serum link Parkinson\u2019s disease severity to peripheral inflammation. Mol Neurodegener. 2024;19(1):47.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"1275_CR58","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/mds.27601","volume":"34","author":"F Atashrazm","year":"2019","unstructured":"Atashrazm F, Hammond D, Perera G, Bolliger MF, Matar E, Halliday GM, et al. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson\u2019s disease patients. Mov Disord. 2019;34(3):406\u201315.","journal-title":"Mov Disord"},{"key":"1275_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar5429","author":"R Di Maio","year":"2018","unstructured":"Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, et al. LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aar5429.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1275_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nchembio.538","volume":"7","author":"X Deng","year":"2011","unstructured":"Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, et al. Characterization of a selective inhibitor of the Parkinson\u2019s disease kinase LRRK2. Nat Chem Biol. 2011;7(4):203\u20135.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"1275_CR61","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"MJ Fell","year":"2015","unstructured":"Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, et al. MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther. 2015;355(3):397\u2013409.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"1275_CR62","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/13543776.2024.2378076","volume":"34","author":"M Morez","year":"2024","unstructured":"Morez M, Lara Ordonez AJ, Melnyk P, Liberelle M, Lebegue N, Taymans JM. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson\u2019s disease: a patent review of the literature to date. Expert Opin Ther Pat. 2024;34(9):773\u201388.","journal-title":"Expert Opin Ther Pat"},{"issue":"48","key":"1275_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk6191","volume":"9","author":"M Sanz Murillo","year":"2023","unstructured":"Sanz Murillo M, Villagran Suarez A, Dederer V, Chatterjee D, Alegrio Louro J, Knapp S, et al. Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures. Sci Adv. 2023;9(48):eadk6191.","journal-title":"Sci Adv"},{"key":"1275_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00193","volume":"14","author":"D Ahmadi Rastegar","year":"2020","unstructured":"Ahmadi Rastegar D, Dzamko N. Leucine rich repeat kinase 2 and innate immunity. Front Neurosci. 2020;14:193.","journal-title":"Front Neurosci"},{"key":"1275_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2025.102482","volume":"93","author":"A Bentley-DeSousa","year":"2025","unstructured":"Bentley-DeSousa A, Clegg D, Ferguson SM. LRRK2, lysosome damage, and Parkinson\u2019s disease. Curr Opin Cell Biol. 2025;93:102482.","journal-title":"Curr Opin Cell Biol"},{"issue":"11","key":"1275_CR66","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1042\/BCJ20253062","volume":"482","author":"SA Buck","year":"2025","unstructured":"Buck SA, Sanders LH. LRRK2-mediated mitochondrial dysfunction in Parkinson\u2019s disease. Biochem J. 2025;482(11):721\u201339.","journal-title":"Biochem J"},{"issue":"12","key":"1275_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.167998","volume":"435","author":"CA Boecker","year":"2023","unstructured":"Boecker CA. The role of LRRK2 in intracellular organelle dynamics. J Mol Biol. 2023;435(12):167998.","journal-title":"J Mol Biol"},{"issue":"273","key":"1275_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa3634","volume":"7","author":"RN Fuji","year":"2015","unstructured":"Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med. 2015;7(273):273ra15.","journal-title":"Sci Transl Med"},{"key":"1275_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0820","author":"MAS Baptista","year":"2020","unstructured":"Baptista MAS, Merchant K, Barrett T, Bhargava S, Bryce DK, Ellis JM, et al. LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aav0820.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1275_CR70","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-020-0893-5","volume":"26","author":"N Whiffin","year":"2020","unstructured":"Whiffin N, Armean IM, Kleinman A, Marshall JL, Minikel EV, Goodrich JK, et al. The effect of LRRK2 loss-of-function variants in humans. Nat Med. 2020;26(6):869\u201377.","journal-title":"Nat Med"},{"issue":"648","key":"1275_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med. 2022;14(648):eabj2658.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1275_CR72","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings D, Huntwork-Rodriguez S, Vissers M, Daryani VM, Diaz D, Goo MS, et al. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease. Mov Disord. 2023;38(3):386\u201398.","journal-title":"Mov Disord"},{"issue":"1","key":"1275_CR73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41531-023-00468-2","volume":"9","author":"KM Merchant","year":"2023","unstructured":"Merchant KM, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman KNH, et al. LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts. NPJ Parkinsons Dis. 2023;9(1):30.","journal-title":"NPJ Parkinsons Dis"},{"key":"1275_CR74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","volume":"8","author":"HT Zhao","year":"2017","unstructured":"Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, et al. LRRK2 antisense oligonucleotides ameliorate alpha-synuclein inclusion formation in a Parkinson\u2019s disease mouse model. Mol Ther Nucleic Acids. 2017;8:508\u201319.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"1275_CR75","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cmdc.202000872","volume":"16","author":"M Konstantinidou","year":"2021","unstructured":"Konstantinidou M, Oun A, Pathak P, Zhang B, Wang Z, Ter Brake F, et al. The tale of proteolysis targeting chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2). ChemMedChem. 2021;16(6):959\u201365.","journal-title":"ChemMedChem"},{"issue":"37","key":"1275_CR76","doi-asserted-by":"publisher","first-page":"16930","DOI":"10.1021\/jacs.2c05499","volume":"144","author":"X Liu","year":"2022","unstructured":"Liu X, Kalogeropulou AF, Domingos S, Makukhin N, Nirujogi RS, Singh F, et al. Discovery of XL01126: a potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2. J Am Chem Soc. 2022;144(37):16930\u201352.","journal-title":"J Am Chem Soc"},{"key":"1275_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129449","volume":"94","author":"JM Hatcher","year":"2023","unstructured":"Hatcher JM, Zwirek M, Sarhan AR, Vatsan PS, Tonelli F, Alessi DR, et al. Development of a highly potent and selective degrader of LRRK2. Bioorg Med Chem Lett. 2023;94:129449.","journal-title":"Bioorg Med Chem Lett"},{"key":"1275_CR78","doi-asserted-by":"publisher","first-page":"1016040","DOI":"10.3389\/fneur.2022.1016040","volume":"13","author":"RK Lesniak","year":"2022","unstructured":"Lesniak RK, Nichols RJ, Montine TJ. Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson\u2019s disease and other diseases for which carriers are at increased risk. Front Neurol. 2022;13:1016040.","journal-title":"Front Neurol"},{"key":"1275_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129487","volume":"95","author":"AW Garofalo","year":"2023","unstructured":"Garofalo AW, Schwarz J, Zobel K, Beato C, Bernardi S, Budassi F, et al. Brain-penetrant cyanoindane and cyanotetralin inhibitors of G2019S-LRRK2 kinase activity. Bioorg Med Chem Lett. 2023;95:129487.","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"1275_CR80","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1042\/BCJ20210375","volume":"478","author":"A Tasegian","year":"2021","unstructured":"Tasegian A, Singh F, Ganley IG, Reith AD, Alessi DR. Impact of Type II LRRK2 inhibitors on signaling and mitophagy. Biochem J. 2021;478(19):3555\u201373.","journal-title":"Biochem J"},{"issue":"23","key":"1275_CR81","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1093\/hmg\/ddu341","volume":"23","author":"T Li","year":"2014","unstructured":"Li T, Yang D, Zhong S, Thomas JM, Xue F, Liu J, et al. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson\u2019s disease cell and mouse models. Hum Mol Genet. 2014;23(23):6212\u201322.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1275_CR82","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1021\/acschemneuro.3c00259","volume":"14","author":"P Pathak","year":"2023","unstructured":"Pathak P, Alexander KK, Helton LG, Kentros M, LeClair TJ, Zhang X, et al. Doubly constrained C-terminal of Roc (COR) domain-derived peptides inhibit leucine-rich repeat kinase 2 (LRRK2) dimerization. ACS Chem Neurosci. 2023;14(11):1971\u201380.","journal-title":"ACS Chem Neurosci"},{"key":"1275_CR83","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50416","author":"K Berndsen","year":"2019","unstructured":"Berndsen K, Lis P, Yeshaw WM, Wawro PS, Nirujogi RS, Wightman M, et al. PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins. Elife. 2019. https:\/\/doi.org\/10.7554\/eLife.50416.","journal-title":"Elife"},{"issue":"3","key":"1275_CR84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/joim.20114","volume":"298","author":"F Camou","year":"2025","unstructured":"Camou F, Berger MG. Gaucher disease, state of the art and perspectives. J Intern Med. 2025;298(3):155\u201372.","journal-title":"J Intern Med"},{"issue":"4","key":"1275_CR85","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher Disease and Parkinsonism: insights from a rare disease. Neuron. 2017;93(4):737\u201346.","journal-title":"Neuron"},{"issue":"17","key":"1275_CR86","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"9","key":"1275_CR87","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","volume":"84","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Amshalom I, Kilarski LL, Bar-Shira A, Gana-Weisz M, Mirelman A, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology. 2015;84(9):880\u20137.","journal-title":"Neurology"},{"issue":"1","key":"1275_CR88","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41531-025-01060-6","volume":"11","author":"A Lanore","year":"2025","unstructured":"Lanore A, Tesson C, Basset A, Lejeune FX, Cogan G, Mangone G, et al. Classification of GBA1 variants and their impact on Parkinson\u2019s disease: an in silico score analysis. NPJ Parkinsons Dis. 2025;11(1):226.","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"1275_CR89","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018;13(2):107\u201318.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1","key":"1275_CR90","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41467-023-37632-4","volume":"14","author":"A Gehrlein","year":"2023","unstructured":"Gehrlein A, Udayar V, Anastasi N, Morella ML, Ruf I, Brugger D, et al. Targeting neuronal lysosomal dysfunction caused by beta-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat Commun. 2023;14(1):2057.","journal-title":"Nat Commun"},{"issue":"457","key":"1275_CR91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","volume":"97","author":"FM Platt","year":"2008","unstructured":"Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr. 2008;97(457):88\u201393.","journal-title":"Acta Paediatr"},{"issue":"1","key":"1275_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00404-5","volume":"11","author":"C Viel","year":"2021","unstructured":"Viel C, Clarke J, Kayatekin C, Richards AM, Chiang MSR, Park H, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945.","journal-title":"Sci Rep"},{"issue":"1","key":"1275_CR93","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10(1):86\u201398.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"1275_CR94","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JPD-212714","volume":"12","author":"MJ Peterschmitt","year":"2022","unstructured":"Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, et al. Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in patients with Parkinson\u2019s disease and a GBA mutation: results from Part 1 of the randomized, double-blinded, placebo-controlled MOVES-PD trial. J Parkinsons Dis. 2022;12(2):557\u201370.","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"1275_CR95","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi N, Alcalay RN, Cutter G, Gasser T, Gurevich T, Hoglinger GU, et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2023;22(8):661\u201371.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1275_CR96","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-022-00363-2","volume":"8","author":"S Blumenreich","year":"2022","unstructured":"Blumenreich S, Nehushtan T, Barav OB, Saville JT, Dingjan T, Hardy J, et al. Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation. NPJ Parkinsons Dis. 2022;8(1):99.","journal-title":"NPJ Parkinsons Dis"},{"issue":"6","key":"1275_CR97","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/mds.28525","volume":"36","author":"J Galper","year":"2021","unstructured":"Galper J, Balwani M, Fahn S, Waters C, Krohn L, Gan-Or Z, et al. Cytokines and Gaucher biomarkers in glucocerebrosidase carriers with and without Parkinson disease. Mov Disord. 2021;36(6):1451\u20135.","journal-title":"Mov Disord"},{"key":"1275_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070823","author":"M Martinez-Bailen","year":"2022","unstructured":"Martinez-Bailen M, Clemente F, Matassini C, Cardona F. GCase enhancers: a potential therapeutic option for Gaucher disease and other neurological disorders. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15070823.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1275_CR99","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nchembio850","volume":"3","author":"RL Lieberman","year":"2007","unstructured":"Lieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, Khanna R, et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2007;3(2):101\u20137.","journal-title":"Nat Chem Biol"},{"issue":"4","key":"1275_CR100","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","volume":"11","author":"F Richter","year":"2014","unstructured":"Richter F, Fleming SM, Watson M, Lemesre V, Pellegrino L, Ranes B, et al. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics. 2014;11(4):840\u201356.","journal-title":"Neurotherapeutics"},{"issue":"35","key":"1275_CR101","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","volume":"284","author":"GH Maegawa","year":"2009","unstructured":"Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem. 2009;284(35):23502\u201316.","journal-title":"J Biol Chem"},{"issue":"Pt 5","key":"1275_CR102","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014;137(Pt 5):1481\u201395.","journal-title":"Brain"},{"key":"1275_CR103","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","volume":"82","author":"G Ambrosi","year":"2015","unstructured":"Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson\u2019s disease cells. Neurobiol Dis. 2015;82:235\u201342.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"1275_CR104","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol. 2016;80(5):766\u201375.","journal-title":"Ann Neurol"},{"issue":"14","key":"1275_CR105","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/hmg\/ddac038","volume":"31","author":"SY Yang","year":"2022","unstructured":"Yang SY, Taanman JW, Gegg M, Schapira AHV. Ambroxol reverses tau and alpha-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Hum Mol Genet. 2022;31(14):2396\u2013405.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1275_CR106","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized noncontrolled trial. JAMA Neurol. 2020;77(4):427\u201334.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1275_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000535","volume":"5","author":"F Colucci","year":"2023","unstructured":"Colucci F, Avenali M, De Micco R, Fusar Poli M, Cerri S, Stanziano M, et al. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson\u2019s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol Open. 2023;5(2):e000535.","journal-title":"BMJ Neurol Open"},{"issue":"1","key":"1275_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03629-9","volume":"24","author":"O Siemeling","year":"2024","unstructured":"Siemeling O, Slingerland S, van der Zee S, van Laar T. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation. BMC Neurol. 2024;24(1):146.","journal-title":"BMC Neurol"},{"issue":"8","key":"1275_CR109","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2025.1687","volume":"82","author":"CRA Silveira","year":"2025","unstructured":"Silveira CRA, Coleman KKL, Borron K, Tirona RG, Rupar CA, Zou G, et al. Ambroxol as a treatment for Parkinson disease dementia: a randomized clinical trial. JAMA Neurol. 2025;82(8):797\u2013807.","journal-title":"JAMA Neurol"},{"issue":"12","key":"1275_CR110","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/mds.28815","volume":"36","author":"D Ysselstein","year":"2021","unstructured":"Ysselstein D, Young TJ, Nguyen M, Padmanabhan S, Hirst WD, Dzamko N, et al. Evaluation of strategies for measuring lysosomal glucocerebrosidase activity. Mov Disord. 2021;36(12):2719\u201330.","journal-title":"Mov Disord"},{"key":"1275_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","volume":"10","author":"D Chiasserini","year":"2015","unstructured":"Chiasserini D, Paciotti S, Eusebi P, Persichetti E, Tasegian A, Kurzawa-Akanbi M, et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Mol Neurodegener. 2015;10:15.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"1275_CR112","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol. 2012;72(3):455\u201363.","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"1275_CR113","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson\u2019s disease. Brain. 2014;137(Pt 3):834\u201348.","journal-title":"Brain"},{"issue":"1","key":"1275_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33921-x","volume":"8","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease. Sci Rep. 2018;8(1):15446.","journal-title":"Sci Rep"},{"issue":"28","key":"1275_CR115","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","volume":"36","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S, et al. A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism. J Neurosci. 2016;36(28):7441\u201352.","journal-title":"J Neurosci"},{"issue":"12","key":"1275_CR116","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1021\/jm300063b","volume":"55","author":"S Patnaik","year":"2012","unstructured":"Patnaik S, Zheng W, Choi JH, Motabar O, Southall N, Westbroek W, et al. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem. 2012;55(12):5734\u201348.","journal-title":"J Med Chem"},{"key":"1275_CR117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6870","author":"LF Burbulla","year":"2019","unstructured":"Burbulla LF, Jeon S, Zheng J, Song P, Silverman RB, Krainc D. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aau6870.","journal-title":"Sci Transl Med"},{"issue":"29","key":"1275_CR118","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Tsunemi T, Toker NJ, Jeon S, Burbulla LF, et al. Activation of beta-glucocerebrosidase reduces pathological alpha-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons. J Neurosci. 2016;36(29):7693\u2013706.","journal-title":"J Neurosci"},{"issue":"9","key":"1275_CR119","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1111\/bcp.14772","volume":"87","author":"JM den Heijer","year":"2021","unstructured":"den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, et al. A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. Br J Clin Pharmacol. 2021;87(9):3561\u201373.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1275_CR120","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/mds.29346","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer JM, Kruithof AC, Moerland M, Walker M, Dudgeon L, Justman C, et al. A phase 1B trial in GBA1-associated Parkinson\u2019s disease of BIA-28-6156, a glucocerebrosidase activator. Mov Disord. 2023;38(7):1197\u2013208.","journal-title":"Mov Disord"},{"key":"1275_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094392","author":"I Fregno","year":"2025","unstructured":"Fregno I, Perez-Carmona N, Rudinskiy M, Solda T, Bergmann TJ, Ruano A, et al. Allosteric modulation of GCase enhances lysosomal activity and reduces ER stress in GCase-related disorders. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26094392.","journal-title":"Int J Mol Sci"},{"key":"1275_CR122","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","volume":"82","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, et al. Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015;82:495\u2013503.","journal-title":"Neurobiol Dis"},{"issue":"s2","key":"1275_CR123","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/JPD-212739","volume":"11","author":"A Abeliovich","year":"2021","unstructured":"Abeliovich A, Hefti F, Sevigny J. Gene therapy for Parkinson\u2019s disease associated with GBA1 mutations. J Parkinsons Dis. 2021;11(s2):S183\u20138.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"1275_CR124","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"AM Pickrell","year":"2015","unstructured":"Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease. Neuron. 2015;85(2):257\u201373.","journal-title":"Neuron"},{"key":"1275_CR125","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2019.04.029","volume":"705","author":"S Miller","year":"2019","unstructured":"Miller S, Muqit MMK. Therapeutic approaches to enhance PINK1\/Parkin mediated mitophagy for the treatment of Parkinson\u2019s disease. Neurosci Lett. 2019;705:7\u201313.","journal-title":"Neurosci Lett"},{"issue":"8","key":"1275_CR126","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/14728222.2024.2392700","volume":"28","author":"A Wu","year":"2024","unstructured":"Wu A, Lee D, Xiong WC. VPS35 or retromer as a potential target for neurodegenerative disorders: barriers to progress. Expert Opin Ther Targets. 2024;28(8):701\u201312.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"1275_CR127","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JPD-230154","volume":"14","author":"L Walker","year":"2024","unstructured":"Walker L, Attems J. Prevalence of concomitant pathologies in Parkinson\u2019s disease: implications for prognosis, diagnosis, and insights into common pathogenic mechanisms. J Parkinsons Dis. 2024;14(1):35\u201352.","journal-title":"J Parkinsons Dis"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01275-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:02:22Z","timestamp":1773489742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01275-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":127,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01275-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ND has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ND is the sole author and agrees to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}